MESO Stock Overview
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 5/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Mesoblast Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | AU$5.01 |
52 Week High | AU$10.24 |
52 Week Low | AU$1.61 |
Beta | 2.59 |
1 Month Change | 116.88% |
3 Month Change | 191.28% |
1 Year Change | -25.45% |
3 Year Change | -71.69% |
5 Year Change | -54.29% |
Change since IPO | -38.54% |
Recent News & Updates
Recent updates
Mesoblast Limited: Back From The Dead
Apr 10Mesoblast GAAP EPS of -$0.14, revenue of $10.21M
Aug 31Mesoblast's remestemcel-L reduces mortality by 46% in patients under age 65 with COVID-19 ARDS
Apr 30Mesoblast issues FQ2 operational and financial update
Jan 29Mesoblast's rexlemestrocel-l reduces heart attacks, strokes
Jan 11Mesoblast: The Future Looks Bleak
Dec 24Mesoblast fails to meet primary endpoint of reduction in recurrent non-fatal heart failure events
Dec 15Mesoblast cell therapy Fast Track'd for COVID-19-related acute respiratory distress syndrome; shares up 14%
Dec 02Mesoblast EPS beats by $0.22, misses on revenue
Nov 19Shareholder Returns
MESO | US Biotechs | US Market | |
---|---|---|---|
7D | -13.6% | -4.2% | -3.7% |
1Y | -25.4% | -2.0% | 20.5% |
Return vs Industry: MESO underperformed the US Biotechs industry which returned -1.7% over the past year.
Return vs Market: MESO underperformed the US Market which returned 20.2% over the past year.
Price Volatility
MESO volatility | |
---|---|
MESO Average Weekly Movement | 28.4% |
Biotechs Industry Average Movement | 11.5% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.4% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: MESO's share price has been volatile over the past 3 months.
Volatility Over Time: MESO's weekly volatility has increased from 19% to 28% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2004 | 83 | Silviu Itescu | www.mesoblast.com |
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
Mesoblast Limited Fundamentals Summary
MESO fundamental statistics | |
---|---|
Market cap | US$549.24m |
Earnings (TTM) | -US$73.06m |
Revenue (TTM) | US$7.47m |
73.6x
P/S Ratio-7.5x
P/E RatioIs MESO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
MESO income statement (TTM) | |
---|---|
Revenue | US$7.47m |
Cost of Revenue | US$48.13m |
Gross Profit | -US$40.66m |
Other Expenses | US$32.40m |
Earnings | -US$73.06m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.064 |
Gross Margin | -544.50% |
Net Profit Margin | -978.41% |
Debt/Equity Ratio | 22.8% |
How did MESO perform over the long term?
See historical performance and comparison